Bausch Health Canada, pCPA sign LOI on public drug plan coverage for PrOKEDI schizophrenia treatment

Bausch Health Companies Inc.
Six Flags Entertainment Corporation

Bausch Health Companies Inc.

BHC

0.00

Six Flags Entertainment Corporation

FUN

0.00
  • Bausch Health reached a letter of intent with Canada’s pan-Canadian Pharmaceutical Alliance for public drug plan coverage of PrOKEDI in schizophrenia.
  • The agreement covers 75 mg and 100 mg doses, setting terms toward product listing agreements with federal, provincial, territorial plans.
  • The step supports broader reimbursement-backed access across Canada for the long-acting injectable risperidone product.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch Health Companies Inc. published the original content used to generate this news brief on June 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.